Compare · APT vs EW
APT vs EW
Side-by-side comparison of Alpha Pro Tech Ltd. (APT) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APT and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $50.78B, about 869.8x APT ($58.4M).
- APT has been more active in the news (14 items in the past 4 weeks vs 5 for EW).
- EW has more recent analyst coverage (25 ratings vs 0 for APT).
- Company
- Alpha Pro Tech Ltd.
- Edwards Lifesciences Corporation
- Price
- -
- -
- Market cap
- $58.4M
- $50.78B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- AMEX
- NYSE
- IPO
- 2000
- News (4w)
- 14
- 5
- Recent ratings
- 0
- 25
Alpha Pro Tech Ltd.
Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through two segments, Disposable Protective Apparel and Building Supply. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap, synthetic roof underlayment, and other woven materials. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites; and pharmaceutical markets. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest APT
- Director Ritota John was granted 5,860 shares, increasing direct ownership by 14% to 47,215 units (SEC Form 4)
- Director Shaw Benjamin A was granted 5,860 shares, increasing direct ownership by 57% to 16,215 units (SEC Form 4)
- Director Buchan James was granted 5,860 shares, increasing direct ownership by 104% to 11,475 units (SEC Form 4)
- Director Garcia David R was granted 5,860 shares, increasing direct ownership by 30% to 25,628 units (SEC Form 4)
- Director Montgomery Charles D covered exercise/tax liability with 13,057 shares, sold $110,593 worth of shares (21,943 units at $5.04) and was granted 33,000 shares, decreasing direct ownership by 3% to 58,281 units (SEC Form 4)
- Amendment: Director Montgomery Charles D sold $152,319 worth of shares (23,886 units at $6.38), decreasing direct ownership by 28% to 60,281 units (SEC Form 4)
- CEO AND PRESIDENT Hoffman Lloyd covered exercise/tax liability with 26,765 shares and was granted 45,000 shares, increasing direct ownership by 7% to 273,750 units (SEC Form 4)
- Director Millar Donna covered exercise/tax liability with 8,029 shares, sold $35,134 worth of shares (6,971 units at $5.04) and was granted 15,000 shares (SEC Form 4)
- CFO Mcdonald Colleen J covered exercise/tax liability with 16,059 shares and was granted 27,000 shares, increasing direct ownership by 20% to 66,774 units (SEC Form 4)
- Amendment: CEO AND PRESIDENT Hoffman Lloyd was granted 50,000 shares, increasing direct ownership by 69% to 122,505 units (SEC Form 4)
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision